A Phase IB/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)

Trial Profile

A Phase IB/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 19 Feb 2016

At a glance

  • Drugs Pazopanib (Primary) ; Docetaxel; Gemcitabine
  • Indications Soft tissue sarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 26 Feb 2015 Last checked against the Robert H. Lurie Comprehensive Cancer Center record.
    • 17 Dec 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 05 Nov 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top